DIZAL
PharmaDIZAL is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include ZEGFROVY.
FDA Novel Drug Designations
(2025)See 1 novel approval →
DIZAL at a Glance
- Fast trial execution (13 months median completion)
DIZAL's Key Drugs
DIZAL's core commercial portfolio centers on ZEGFROVY, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
DIZAL's Recent FDA Approvals
DIZAL secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
DIZAL's Therapeutic Areas
DIZAL's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DIZAL's Top Competitors
DIZAL's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DIZAL Pipeline Snapshot
DIZAL has 32 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 9 Phase 2 and 19 Phase 1.
Phase 3 Readout Calendar Pro
3 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZEGFROVY leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/2 completed
- • Speed: 13 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-07-02
- Latest
- 2025-07-02
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges